For instance, the monoclonal antibody Trastuzumab (Herceptin®, Roche Pharma, Grenzach-Wyhlen, Alemania) recognizes the HER2/neu receptor (human epidermal growth factor receptor 2), which is overexpressed in multiple cancers, such as breast, lung and ovarian cancer [4]. Here, ERBB2 is linked to ovarian carcinoma.